Launchpad12 LLC completed the acquisition of an additional 39.75% stake in Gene Techno Science Co., Ltd. from DyDo DRINCO, INC., Japan Securities Finance Co. Ltd., Asset Management Arm, SBI Holdings Inc., Asset Management Arm, Senju Pharmaceutical Co.,Ltd. and others for ¥5.4 billion.
May 30, 2016
Share
Launchpad12 LLC offered to acquire remaining 81.99% stake in Gene Techno Science Co., Ltd. (TSE:4584) from DyDo DRINCO, INC., Japan Securities Finance Co. Ltd., Asset Management Arm, SBI Holdings Inc., Asset Management Arm, Senju Pharmaceutical Co.,Ltd. and others for ¥11.1 billion on March 28, 2016. Under the terms, Noritsu Koki offered a takeover bid for 3.72 million shares of Gene Techno Science at ¥3000 per share. In a related deal, Gene Techno Science passed a resolution to conduct an issuance of new shares towards Launchpad12 LLC by third-party allocation. Post-acquisition, Noritsu Koki's stake in Gene Techno Science will increase to 100% from 18.01%. Offering period starts from April 15, 2016 to May 30, 2016 and settlement will start on June 6, 2016.
Yamada FAS Co., Ltd. acted as financial advisor and Abe, Ikubo & Katayama acted as legal advisor for Gene Techno Science and Abe, Ikubo and Katayama as legal advisor for fairness and rationality of decision-making processes and methods. Nomura Securities Co., Ltd. acted as tender offer agent in the transaction. Plutus Consulting Co., Ltd. acted as valuer for Launchpad12 LLC.
Launchpad12 LLC completed the acquisition of an additional 39.75% stake in Gene Techno Science Co., Ltd. (TSE:4584) from DyDo DRINCO, INC., Japan Securities Finance Co. Ltd., Asset Management Arm, SBI Holdings Inc., Asset Management Arm, Senju Pharmaceutical Co.,Ltd. and others for ¥5.4 billion on May 31, 2016. Under the terms, Launchpad12 LLC acquired 1.8 million shares and increased the shareholding to 2.62 million shares (57.76%) in Gene Techno Science Co., Ltd.
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
KIDSWELL BIO CORPORATION 
